Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Podcasts|February 19, 2021
- Ophthalmology Times: February 1, 2021
- Volume 46
- Issue 2
EyePod: Ophthalmologist shares Holocaust survival story
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
In this latest EyePod episode, John H. Merey, MD, possibly one of the last Holocaust survivors still in the practice of ophthalmology, shares his experience.
Advertisement
Read Dr. Merey's story:
Watch the interview:
Articles in this issue
over 5 years ago
Do you 'need' or just 'want' that new diagnostic imaging device?over 5 years ago
Noninvasive angiography with OCT offers definite valueover 5 years ago
Ophthalmology residents retrained as palliative care extendersover 5 years ago
How AAOOP is taking the pandemic by the hornsover 5 years ago
Investigators examine anti-VEGF medications in cases with ROPover 5 years ago
Tool offers ultra-rapid cooling for intravitreal injectionsAdvertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Brepocitinib meets all Phase 3 end points in noninfectious uveitis
2
Demodex blepharitis: Diagnosis, treatment response, and recurrence
3
Matching artificial tears to dry eye phenotype: a Q&A with Omur Ucakhan, MD
4
SpyGlass Pharma's BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5